Hansoh Pharma stock weighs pipeline gains against EU setback

Published on 10/07/2026 at 07:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hansoh Pharma stock traded at HKD 33.66 on October 7, 2026, while an EU authorization setback tests its global pipeline. First-half profit rose 35.82 percent.

Hansoh Pharma, KYG549581067, Illustration mit AI erstellt.

Hansoh Pharma stock (ISIN KYG549581067) was trading at HKD 33.66 on HKEX on October 7, 2026 at 1:14 p.m. HKT, down 2.72 percent. The European Commission's September 25 decision on Aumseqa adds a regulatory counterweight to the company's recent clinical progress.

EU setback meets pipeline progress

As Novapharma News reported on October 5, 2026, the European Commission revoked Aumseqa's EU marketing authorization after identifying a procedural issue involving protected AstraZeneca data. Hansoh said the decision did not concern the drug's quality, safety or efficacy and plans to resubmit the application to the European Medicines Agency.

The setback matters mainly to Hansoh's international expansion. The company said Aumseqa had generated no sales revenue outside China as of the announcement, limiting the immediate earnings effect while keeping the regulatory process relevant to the pipeline narrative.

Phase 3 data add a counterweight

In its release dated September 21, 2026, Hansoh Pharma said its oral TYK2 inhibitor HS-10374 met both co-primary endpoints in a Phase 3 psoriasis trial. At week 16, more than half of treated participants achieved PASI 90, while the PASI 75 and sPGA 0/1 response rates were significantly higher than placebo.

That clinical result supports the company's innovation strategy, but the release gave no numerical response rates for the two co-primary endpoints. Hansoh said it would begin discussions with China's National Medical Products Administration on preparations for a new drug application.

Profit growth outpaces revenue

Hansoh's latest reported period was the six months ended June 30, 2026. According to GMT Eight on August 26, 2026, revenue rose 11.71 percent year over year to RMB 8.304 billion, while profit attributable to shareholders increased 35.82 percent to RMB 4.258 billion. Basic earnings per share were RMB 0.70, and the proposed interim dividend was HKD 0.285 per share.

The operating mix is shifting toward innovation. Hansoh's official website says innovative medicines generate more than 80 percent of product sales revenue in China, while the group has marketed 7 innovative drugs and maintains more than 30 programs in clinical development.

Consensus stays above the quote

MarketScreener lists a Buy consensus from 24 analysts and an average target price of CNY 40.86. The consensus is a separate market expectation from Hansoh's reported results and does not remove the regulatory execution risk around overseas approvals.

Stock remains below yearly high

Hansoh Pharma stock was trading at HKD 33.66 on HKEX on October 7, 2026, against a 52-week range of HKD 28.06 to HKD 44.22 and a market capitalization of HKD 204.1 billion. The HKEX quote was down 2.72 percent on the session, putting the immediate market signal at odds with the company's stronger first-half profit growth.